查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566812

心臟病诊断市场：按类型、最终用户划分：2024-2033 年全球机会分析与产业预测

Heart Attack Diagnostics Market By Type (Electrocardiogram, Blood Tests, Angiogram, Computerized Cardiac Tomography, Others), By End User (Hospitals, Diagnostics Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 260 Pages | 商品交期: 2-3个工作天内

价格
简介目录

心臟病诊断市场

2023 年心臟病诊断市场价值为 92 亿美元，预计 2024 年至 2033 年复合年增长率为 8.6%，到 ​​2033 年达到 211 亿美元。

心臟病发作诊断包括诊断患者的血压、体温和脉搏率。将进行一系列评估以确定您是否经历过心臟病发作，也称为心肌梗塞。一系列诊断测试包括测量心臟电活动的心电图 (EKG) 和检测心肌酵素（例如肌钙蛋白）的血液测试，心肌酵素在心肌受损时会释放到血液中，其中包括成像测试等。冠动脉摄影术和超音波心动图的可视化。

久坐生活方式的增加导致文明病急剧增加，包括心臟病发作。因此，心臟病诊断的需求激增，加速了市场的成长。此外，全球老年人口的快速成长正在为市场扩张铺平道路。将人工智慧引入心电图测试可能会成为未来的主流，因为这将缩短诊断时间。台湾一家医院进行AI与心电图同化研究，将诊断时间缩短10分钟。人工智慧的不断改进正在提高临床决策支援系统的有效性，并鼓励医疗保健专业人员采用这项技术。

然而，这些诊断测试非常昂贵，导致最终用户无法利用其优势并抑制市场开拓。此外，引进新诊断技术还存在各种监管障碍，这为市场扩张带来了挑战。包括美国食品药物管理局、欧洲药品管理局、日本药品和医疗设备管理局以及印度中央药品标准控制组织在内的各个监管机构都要求新诊断技术遵守各自的监管指南才能进入市场。相反，将创新技术引入市场表明其前景光明。例如，德国医疗公司西门子医疗公司推出了一款手持设备，声称可以在 30 分钟内检测出心臟病发作。希望此类设备的推出将加快治疗速度并增加患者康復的机会。

按部门审查

心臟病诊断市场分为类型、最终用户和地区。依类型划分，市场分为心电图、血液检查、血管造影术、电脑心臟断层扫描等。依最终用户划分，可分为医院、诊断中心等。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

该报告可以定制。

  • 根据客户兴趣加入公司简介
  • 扩大公司简介列表
  • 历史市场资料

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章心臟病诊断市场：按类型

  • 市场概况
  • 心电图
  • 验血
  • 血管造影术
  • 电脑心臟断层扫描
  • 其他的

第五章心臟病诊断市场：依最终用户分类

  • 市场概况
  • 医院
  • 诊断中心
  • 其他的

第六章心臟病诊断市场：按地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国心臟病诊断市场
    • 加拿大心臟病诊断市场
    • 墨西哥心臟病诊断市场
  • 欧洲
    • 主要市场趋势和机会
    • 法国心臟病诊断市场
    • 德国心臟病诊断市场
    • 义大利心臟病诊断市场
    • 西班牙心臟病诊断市场
    • 英国心臟病诊断市场
    • 其他欧洲心臟病诊断市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国心臟病诊断市场
    • 日本心臟病诊断市场
    • 印度心臟病诊断市场
    • 韩国心臟病诊断市场
    • 澳洲心臟病诊断市场
    • 其他亚太心臟病诊断市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西心臟病诊断市场
    • 南非心臟病诊断市场
    • 沙乌地阿拉伯心臟病诊断市场
    • 其他拉丁美洲/中东/非洲心臟病诊断市场

第七章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第八章 公司简介

  • Bionet Co., Ltd
  • TOSHIBA CORPORATION
  • Bio-Rad Laboratories Inc
  • Life Sign LLC
  • Schiller AG
  • Beckman Coulter, Inc.
  • GE Healthcare
  • Hitachi Medical Systems
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
简介目录
Product Code: A12689

Heart Attack Diagnostics Market

The heart attack diagnostics market was valued at $9.2 billion in 2023 and is projected to reach $21.1 billion by 2033, growing at a CAGR of 8.6% from 2024 to 2033.

Heart attack diagnostic comprises of diagnosing the blood pressure, temperature, and pulse rate of a patient. A series of evaluations are conducted to determine if an individual has experienced a heart attack, also known as myocardial infarction. The series of diagnostic tests includes an electrocardiogram (EKG) which measures the electrical activity of heart, blood tests to detect cardiac enzymes such as troponin which are released into the bloodstream in case of heart muscle damage, and imaging tests such as coronary angiography or echocardiography for the visualization of heart & its blood vessels.

Increase in sedentary lifestyles has led to surge in occurrence of lifestyle diseases, including heart attack. This has led to surge in demand for heart attack diagnostics, hence augmenting the growth of the market. Furthermore, exponential growth in the geriatric population globally is opening avenues for the expansion of the market. The assimilation of AI in the EKG testing is poised to become mainstream in the future as it reduces the diagnosis time. A hospital in Taiwan conducted research regarding the assimilation of AI and EKG, which reduced the diagnosis period by 10 minutes. Constant improvements in AI are enhancing the efficacy of clinical decision support system, encouraging medical practitioners to adopt the technology.

However, these diagnostics tests are extremely expensive and prevent several end users from leveraging their benefits, hence restraining the market development. In addition, the introduction of new diagnostic technologies is subject to various regulatory hurdles, hence presenting challenges for the expansion of the market. Different regulatory bodies such as the U.S. Food and Drug Administration, European Medicines Agency, the Pharmaceuticals and Medical Devices Agency in Japan, and Central Drugs Standard Control Organization in India have mandated the adherence to their respective regulatory guidelines for the entry of new diagnostic technologies into the market. Contrarily, innovative techniques being introduced into the market are an indicator of its promising future. For instance, Siemens Healthineers, a German healthcare company, has introduced a handheld device which claims to detect heart attack in less than 30 minutes. The launch of such devices is expected to quicken treatment delivery and increase the chances of recovery for patients in the future.

Segment Review

The heart attack diagnostics market is segmented into type, end user, and region. On the basis of type, the market is divided into electrocardiogram, blood tests, angiogram, computerized cardiac tomography, and others. By end user, it is classified into hospitals, diagnostics centers, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Competition Analysis

The major players operating in the global heart attack diagnostics market include Bionet Co., Ltd, TOSHIBA CORPORATION, Bio-Rad Laboratories Inc, Life Sign LLC, Schiller AG, Beckman Coulter,Inc., GE Healthcare, Hitachi Medical Systems, F. Hoffmann-La Roche Ltd., and Abbott Laboratories. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Type

  • Electrocardiogram
  • Blood Tests
  • Angiogram
  • Computerized Cardiac Tomography
  • Others

By End User

  • Hospitals
  • Diagnostics Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Bionet Co., Ltd
    • TOSHIBA CORPORATION
    • Bio-Rad Laboratories Inc
    • Life Sign LLC
    • Schiller AG
    • Beckman Coulter,Inc.
    • GE Healthcare
    • Hitachi Medical Systems
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities

CHAPTER 4: HEART ATTACK DIAGNOSTICS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Electrocardiogram
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Blood Tests
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Angiogram
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Computerized Cardiac Tomography
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country
  • 4.6. Others
    • 4.6.1. Key Market Trends, Growth Factors and Opportunities
    • 4.6.2. Market Size and Forecast, By Region
    • 4.6.3. Market Share Analysis, By Country

CHAPTER 5: HEART ATTACK DIAGNOSTICS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Diagnostics Centers
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Others
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: HEART ATTACK DIAGNOSTICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Heart Attack Diagnostics Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Heart Attack Diagnostics Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Heart Attack Diagnostics Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. France Heart Attack Diagnostics Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. Germany Heart Attack Diagnostics Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. Italy Heart Attack Diagnostics Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Spain Heart Attack Diagnostics Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. UK Heart Attack Diagnostics Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Heart Attack Diagnostics Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Heart Attack Diagnostics Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. Japan Heart Attack Diagnostics Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. India Heart Attack Diagnostics Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. South Korea Heart Attack Diagnostics Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. Australia Heart Attack Diagnostics Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Heart Attack Diagnostics Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Heart Attack Diagnostics Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. South Africa Heart Attack Diagnostics Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. Saudi Arabia Heart Attack Diagnostics Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Heart Attack Diagnostics Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Bionet Co., Ltd
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. TOSHIBA CORPORATION
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Bio-Rad Laboratories Inc
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Life Sign LLC
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Schiller AG
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Beckman Coulter, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. GE Healthcare
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Hitachi Medical Systems
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. F. Hoffmann-La Roche Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Abbott Laboratories
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments